![Fidah bin Ismail Alsagoff](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Fidah bin Ismail Alsagoff
Director/Miembro de la Junta en Tychan Pte Ltd. .
Cargos activos de Fidah bin Ismail Alsagoff
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Tychan Pte Ltd.
![]() Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Director/Miembro de la Junta | - | - |
Historial de carrera de Fidah bin Ismail Alsagoff
Estadísticas
Internacional
Singapur | 2 |
Operativa
Director/Board Member | 1 |
Sectorial
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Tychan Pte Ltd.
![]() Tychan Pte Ltd. BiotechnologyHealth Technology Tychan Pte Ltd. is a clinical-stage biotechnology company based in Singapore that focuses on developing life-saving treatments for emerging infections through disruptive technologies. Tychan was founded by Professor Ram Sasisekharan of Massachusetts Institute of Technology (MIT)/Singapore MIT Alliance for Research and Technology (SMART) and Professor Ooi Eng Eong of Duke-National University of Singapore (Duke-NUS) Medical School, both of whom have expertise in biologics development and biology of acute viral infections. The private company is based in Singapore, Singapore, and Randall E. Woods has been the CEO of the company since 2021. The Singaporean company works closely with regulatory authorities to accelerate the translation from non-clinical studies to clinical trials for emerging pathogens. Temasek Holdings is the founding investor of Tychan. | Health Technology |